Vantage logo

Calithera buys itself a plan B

With telaglenastat facing a risky trial readout Calithera picks up two bargain-basement oncology projects to pivot to.

Vantage logo

Treme climbs a new mountain

Astrazeneca’s Himalaya study is a surprising hit in first-line liver cancer, but competition is already present.